PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2010 | 90 |
| 2011 | 155 |
| 2012 | 186 |
| 2013 | 252 |
| 2014 | 1019 |
| 2015 | 3527 |
| 2016 | 6840 |
| 2017 | 10218 |
| 2018 | 2421 |
| 2019 | 734 |
| 2020 | 416 |
| 2021 | 258 |
| 2022 | 159 |
| 2023 | 179 |
| 2024 | 124 |
| 2025 | 130 |
| 2026 | 91 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Oncotarget"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
Emerging biomedical imaging applications of tumor-derived extracellular vesicles for premetastatic niche detection: Biological rationale, engineering strategies, and translational challenges.
- Dhaygude O, Chen Y, Suguru Y, Brock M, Housseau F, Michel J.
- Oncotarget. 2026 Aug 28;17(1):389-412. doi: 10.18632/oncotarget.28916.
- PMCID: PMC13637956
Dhaygude O, et al.Oncotarget. 2026.PMCID: PMC13637956 -
Editorial Note: Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.
- Huggett MT, Tudzarova S, Proctor I, Loddo M, Keane MG, Stoeber K, Williams GH, Pereira SP.
- Oncotarget. 2026 Jan 6;17(1):388. doi: 10.18632/oncotarget.28902.
- PMCID: PMC13637950
Huggett MT, et al.Oncotarget. 2026.PMCID: PMC13637950 -
Correction: Positive feedback loop of IL-1β/Akt/RARα/Akt signaling mediates oncogenic property of RARα in gastric carcinoma.
- Ren HY, Liu F, Huang GL, Liu Y, Shen JX, Zhou P, Liu WM, Shen DY.
- Oncotarget. 2026 Jan 6;17(1):379-380. doi: 10.18632/oncotarget.28906.
- PMCID: PMC13637958
Ren HY, et al.Oncotarget. 2026.PMCID: PMC13637958 -
Gut feeling: Microbes at the heart of cancer therapy.
- Saqib U, Ratlamwala S, Pandey M, Hajela K.
- Oncotarget. 2026 Jan 6;17(1):430-433. doi: 10.18632/oncotarget.28919.
- PMCID: PMC13637953
Saqib U, et al.Oncotarget. 2026.PMCID: PMC13637953 -
Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
- Jiang SH, Wang Y, Yang JY, Li J, Feng MX, Wang YH, Yang XM, He P, Tian GA, Zhang XX, Li Q, Cao XY, Huo YM, Yang MW, Fu XL, Li J, Liu DJ, Dai M, Wen SY, Gu JR, Hong J, Hua R, Zhang ZG, Sun YW.
- Oncotarget. 2026 Jan 6;17(1):428-429. doi: 10.18632/oncotarget.28909.
- PMCID: PMC13637961
-
- Retracts: Oncotarget. 2016 Jan 26;7(4):4226-40. doi: 10.18632/oncotarget.6772. PubMed Abstract
Jiang SH, et al.Oncotarget. 2026.PMCID: PMC13637961Retraction notice. -
Are both COVID-19 and COVID-19 vaccines associated with cancer?
- Lataster R.
- Oncotarget. 2026 Sep 11;17(1):426-427. doi: 10.18632/oncotarget.28918.
- PMCID: PMC13637951
Lataster R.Oncotarget. 2026.PMCID: PMC13637951 -
Retraction: Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.
- Kim JO, Kim KH, Song IS, Cheon KS, Kim OH, Lee SC, Lee SK, Kim SJ.
- Oncotarget. 2026 Jan 6;17(1):413. doi: 10.18632/oncotarget.28910.
- PMCID: PMC13637960
-
- Retracts: Oncotarget. 2017 Jan 10;8(2):2936-2948. doi: 10.18632/oncotarget.13808. PubMed Abstract
Kim JO, et al.Oncotarget. 2026.PMCID: PMC13637960Retraction notice. -
Re-expression of MHC-I to treat CNS cancers.
- Yuzhalin AE.
- Oncotarget. 2026 Sep 8;17(1):414-425. doi: 10.18632/oncotarget.28917.
- PMCID: PMC13637955
Yuzhalin AE.Oncotarget. 2026.PMCID: PMC13637955 -
Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.
- Crane K, Bhat KRS, Grivas P, Necchi A, Bratslavsky G, Shapiro O, Jacob JM, Goldberg H, Sager R, Ross JS.
- Oncotarget. 2026 Aug 19;17(1):381-387. doi: 10.18632/oncotarget.28912.
- PMCID: PMC13637952
Crane K, et al.Oncotarget. 2026.PMCID: PMC13637952 -
Systematic methodological flaws in DNA contamination assessment of mRNA vaccines: A critical analysis of Achs et al. (2025).
- McKernan K, Speicher DJ, Rose J.
- Oncotarget. 2026 Aug 14;17(1):368-376. doi: 10.18632/oncotarget.28913.
- PMCID: PMC13637954
McKernan K, et al.Oncotarget. 2026.PMCID: PMC13637954